Considering increasing reports of the association between Hashimoto thyroiditis and thyroid cancer [36], we strongly propose that LMP2 might be a potential therapeutic target for the protective treatment of oncocytic lesions and hypothyroidism as well. The gene discussed is PSMB9; the disease is Hashimoto thyroiditis.